G1 Therapeutics, Inc. / Fundamentals
Income statement
- Net revenue
€49.64M - Cost of goods sold
€5.24M - Gross profit
€44.40M - SG&A expenses
€51.76M - R&D expenses
€24.95M - EBITDA
-€30.20M - D&A
€419.65K - EBIT
-€32.31M - Interest expenses
€7.63M - EBT
-€36.65M - Tax expenses
€1.61M - Net income
-€38.19M
Cash flow statement
- Net deferred tax
€498.12K - Non-cash items
€4.41M - Changes in working capital
-€4.25M - Operating cash flow
-€32.02M - Capex
€0.00 - Other investing cash flow
-€379.56K - Net investing cash flow
€4.33M - Total cash dividends paid
€0.00 - Issuance of common stock
€458.89K - Debt repayment
-€8.43M - Other financing cash flow
€996.25K - Net financing cash flow
-€7.19M - Foreign exchange effects
€0.00 - Net change in cash
-€34.89M - Cash at end of period
€12.91M - Free cash flow
-€32.02M
Balance sheet
- Cash and cash equivalents
€12.91M - Cash and short-term investments
€51.85M - Total receivables
€11.35M - Inventory
€11.42M - Other current assets
€4.69M - Total current assets
€79.26M - Property, plant & equipment
€4.76M - Goodwill
€0.00 - Intangible assets
€0.00 - Long-term investments
€159.50K - Other non-current assets
€0.00 - Total non-current assets
€4.92M - Total assets
€84.18M - Accounts payable
€4.40M - Short-term debt
€9.73M - Other current liabilities
€17.05M - Total current liabilities
€31.99M - Long-term debt
€31.18M - Deferred tax liabilities
€0.00 - Other non-current liabilities
€34.97K - Total non-current liabilities
€31.21M - Total liabilities
€63.20M - Common stock
€4.26K - Retained earnings
-€678.67M - Other equity
€0.00 - Total equity
€20.98M - Total liabilities and shareholders' equity
€84.18M
Company information
- Market capitalization
€322.20M - Employees
100 - Enterprise Value
€410.58M
Company ratios
- Gross margin
-
89.4% Much worse than peer group: 1,126,961,787,785,738,600.0% - EBITDA margin
-
-60.9% Much better than peer group: -31,657,950,571,477,310,000.0% - EBIT margin
-
-65.1% Much better than peer group: -36,174,460,508,358,925,000.0% - EBT margin
-
-73.8% Much better than peer group: -34,918,756,397,134,074,000.0% - Net margin
-
-76.9% Much better than peer group: -34,967,534,544,524,060,000.0% - ROE
-
-182.1% Much worse than peer group: -59.7% - ROA
-
-45.4% Much better than peer group: -236.6% - Asset turnover
-
59.0% Much better than peer group: 19.4% - FCF margin
-
-64.5% Much better than peer group: -28,428,330,774,479,702,000.0% - FCF yield
-9.9% - Efficiency ratio
160.9% - Net sales per employee
-
€496.37K - Net income per employee
-
-€381.87K